Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	75089
Country	Egypt

Received	2022-01-15 22:43
Peer-Review Started	2022-01-15 22:43
To Make the First Decision
Return for Revision	2022-03-13 03:11
Revised	2022-03-19 22:57
Second Decision	2022-05-07 07:56
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-05-08 07:20
Articles in Press	2022-05-08 07:20
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-05-31 21:45
Publish the Manuscript Online	2022-06-10 02:05

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event
Manuscript Source	Invited Manuscript
All Author List	Walaa Abdelhamed and Mohamed El-Kassas
ORCID	Author(s) ORCID Number Walaa Abdelhamed http://orcid.org/0000-0002-5596-4769 Mohamed El-Kassas http://orcid.org/0000-0002-3396-6894
Funding Agency and Grant Number
Corresponding Author	Mohamed El-Kassas, MD, Full Professor, Department of Endemic Medicine, Faculty of Medicine, Helwan University, Helwan, Cairo 11795, Egypt. m_elkassas@yahoo.com
Key Words	Fibrolamellar carcinoma; Hepatocellular carcinoma; Hepatitis; Cirrhosis; Viral hepatitis infection
Core Tip	Fibrolamellar carcinoma (FLC) is a rare liver cancer that displays unique features in behavior and clinical findings from conventional hepatocellular carcinoma (HCC). No certain underlying trigger is detected in FLC. Alpha-fetoprotein levels are normal, unlike in traditional HCC. Surgery (resection/liver transplantation) is the current mainstay of treatment and remains the only curative option. FLCs have been less chemo-responsive than the conventional HCC. Controlled trials evaluating checkpoint inhibitors in FLC are lacking. In this review, we collect and summarize current evidence and clinical experience of conversion therapy, highlight remaining problems and challenges for further research.
Publish Date	2022-06-10 02:05
Citation	Abdelhamed W, El-Kassas M. Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event. World J Gastrointest Oncol 2022; 14(6): 1103-1114
URL	https://www.wjgnet.com/1948-5204/full/v14/i6/1103.htm
DOI	https://dx.doi.org/10.4251/wjgo.v14.i6.1103

Full Article (PDF)	WJGO-14-1103.pdf
Full Article (Word)	WJGO-14-1103.docx
Manuscript File	75089_Auto_Edited-YJM.docx
Answering Reviewers	75089-Answering reviewers.pdf
Audio Core Tip	75089-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	75089-Conflict-of-interest statement.pdf
Copyright License Agreement	75089-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	75089-Language certificate.pdf
Peer-review Report	75089-Peer-review(s).pdf
Scientific Editor Work List	75089-Scientific editor work list.pdf